Compare VPG & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VPG | TSHA |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2010 | 2020 |
| Metric | VPG | TSHA |
|---|---|---|
| Price | $92.67 | $5.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $53.50 | $11.63 |
| AVG Volume (30 Days) | 452.9K | ★ 2.9M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $307,202,000.00 | $9,773,000.00 |
| Revenue This Year | $7.21 | N/A |
| Revenue Next Year | $6.92 | $1,152.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 0.22 | ★ 17.28 |
| 52 Week Low | $25.58 | $2.63 |
| 52 Week High | $151.78 | $7.30 |
| Indicator | VPG | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 40.81 | 47.23 |
| Support Level | $37.49 | $5.28 |
| Resistance Level | $150.08 | $6.01 |
| Average True Range (ATR) | 8.14 | 0.39 |
| MACD | -1.60 | 0.00 |
| Stochastic Oscillator | 39.83 | 48.48 |
Vishay Precision Group Inc manufactures and markets sensors and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.